Elpiscience Biopharma Ltd.

ACTIVE

上海市（市辖区）, 上海市, Chinawww.elpiscience.comHolding51–100 employeesEstablished: 2017-09-30

Part of elpiscience biopharmaceuticals co., limited

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2017

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

100.0%

Trial Status Distribution

Completed

50.0%

Terminated

16.7%

Withdrawn

33.3%

Clinical Trials

Trials sponsored by this organization (6)

A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

interventional

Dec 20218 participants

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Phase 1

Completed

interventional

Oct 202130 participants

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors

A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

Phase 1

Completed

interventional

Apr 202118 participants

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

Phase 1

Terminated

interventional

Jun 201922 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations